Home Team Science News Contact


STX-100 Phase 2 Trial in Idiopathic Pulmonary Fibrosis Now Recruiting Patients
GO >x
MORE NEWS >
x
x
Download our Company
Fact Sheet
DOWNLOAD (PDF) >
x
x
Follow Stromedix on Twitter
GO >x

  
Michael Gilman, Ph.D.
Founder and Chief Executive Officer
Mike most recently served as Executive Vice President, Research at Biogen Idec and previously as Chief Scientific Officer of ARIAD Pharmaceuticals. He spent eight years on the scientific staff of Cold Spring Harbor Laboratory.

Brad Maroni, M.D.
Chief Medical Officer
Brad was most recently Chief Medical Officer at RenaMed Biologics. Prior to that, he was Vice President, Clinical Development at Amgen, where he was responsible for clinical development within the Anemia/Nephrology therapeutic area. He had previously spent ten years at Emory University conducting basic and clinical research.

Shelia Violette, Ph.D.
Vice President, Research
Shelia was most recently Director in Immunology at Biogen Idec and previously the Research Head for the Fibrosis focus area and project leader for the αvβ6 program. Prior to Biogen Idec, Shelia worked at ARIAD Pharmaceuticals and Repligen and has extensive experience from discovery to preclinical development in multiple therapeutic areas.

Dan Lynch
Executive Chairman
Dan served as CEO, CFO and a Director of ImClone Systems Inc. He also served for 15 years in various financial capacities at Bristol-Myers Squibb Company, including Vice President positions for the U.S. Pharmaceuticals business, Worldwide Manufacturing operations, International Pharmaceuticals business, and the Worldwide Consumer Medicines business.


board
Dan Lynch
Executive Chairman

Michael Gilman, Ph.D.
Founder and Chief Executive Officer

Peter Barrett, Ph.D.
Atlas Venture

Chris Gabrieli
Bessemer Venture Partners

Ron Hunt
New Leaf Venture Partners

  
STX-100 is Stromedix's first clinical candidate and is being developed for the treatment of idiopathic pulmonary fibrosis.

Humanized monoclonal antibody to integrin αvβ6
Completed phase 1 clinical testing
Provides localized, injury-specific inhibition of TGF-β activation
Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease
Broad therapeutic utility in chronic organ failure, acute organ failure and cancer
Phase 2 clinical trial for patients with idiopathic pulmonary fibrosis now open. More information at ClinicalTrials.gov.